Antibiotic Crisis Is India's Healthcare Delivery Failure

India's antibiotic crisis is less a story about failing drugs than about a failing system for delivering healthcare. A landmark study by the Indian Council of Medical Research (ICMR), published in The Lancet Regional Health – Southeast Asia in October 2026, tracked more than 150,000 patients across 20 tertiary-care hospitals over three years, representing over 1.75 million patient-days of care. Among 26,213 patients with confirmed bacterial infections, 61.1 per cent carried infections resistant to carbapenems — the last-resort antibiotics doctors use when everything else fails. For AMR India researchers, the findings confirm that antimicrobial resistance is now entrenched in the country's hospitals.

Carbapenems are the antibiotics of last resort: when they fail, treatment options shrink to almost nothing. That the antibiotic crisis has reached the point where three in five confirmed infections in major hospitals resist these drugs underscores how quickly the window for effective treatment is closing in India.

The antibiotic crisis in the numbers

The antibiotic crisis shows up most clearly in mortality figures. The study examined four Gram-negative pathogens — E. coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa. Death rates were consistently higher when infections were resistant: Klebsiella pneumoniae killed 31.2 per cent of patients with resistant infections versus 23.5 per cent with susceptible ones; E. coli 24.4 per cent versus 17.3 per cent; Acinetobacter baumannii 37.9 per cent versus 32.8 per cent; Pseudomonas aeruginosa 28.9 per cent versus 20.2 per cent. In carbapenem-resistant infections, mortality reached 46.4 to 50.8 per cent. The work, led by ICMR researchers including Dr Kamini Walia, Dr Sonam Vijay and Dr Nitin Bansal, is the largest of its kind conducted in India.

Why the antibiotic crisis is a healthcare delivery failure

The numbers describe resistance; the causes describe a system for delivering healthcare in disarray. Antibiotics remain available over the counter across much of India, enabling widespread self-medication. Broad-spectrum antibiotics are routinely over-prescribed for viral infections, while bacterial-culture testing rates in hospitals remain low — meaning doctors often prescribe blind. India's private antibiotic market, estimated at five billion doses, feeds the antibiotic crisis directly with heavy use of "Watch" group antibiotics that should be carefully reserved. Antibiotic use in livestock and agriculture, along with pharmaceutical wastewater, spreads resistance into the environment. Enforcement of the Clinical Establishments Act remains weak, and pharma marketing incentives continue to influence prescribing. The result is a healthcare delivery system that has made India a hotspot for superbugs: antimicrobial resistance thrives not because the science is unknown, but because stewardship is not enforced.

Fixing the antibiotic crisis starts with the system

India's crisis mirrors a global one. The World Health Organization lists antimicrobial resistance among its top 10 global health threats, and AMR was associated with an estimated 1.27 million deaths worldwide in 2019. Projections suggest up to 10 million annual AMR deaths globally by 2050 if the trend continues unchecked. The GARDP findings add an access dimension to the AMR India debate: a study by the Global Antibiotic Research and Development Partnership found that only 7.8 per cent of patients with carbapenem-resistant Gram-negative infections across eight countries including India received suitable treatment, with roughly 3.5 lakh deaths attributed to that access gap. Addressing the antibiotic crisis will therefore require repairing the way healthcare is delivered — enforcing prescription rules, expanding diagnostic testing, regulating antibiotic use in agriculture, and cleaning up pharmaceutical waste — as much as discovering new drugs.